Copyright
©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 28, 2006; 12(28): 4461-4465
Published online Jul 28, 2006. doi: 10.3748/wjg.v12.i28.4461
Published online Jul 28, 2006. doi: 10.3748/wjg.v12.i28.4461
Living donor liver transplantation to patients with hepatitis C virus cirrhosis
Yasuhiko Sugawara, Masatoshi Makuuchi, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
Supported by Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan
Correspondence to: Yasuhiko Sugawara, MD, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. yasusuga-tky@umin.ac.jp
Telephone: +81-3-38155411 Fax: +81-3-56843989
Received: September 12, 2005
Revised: October 12, 2005
Accepted: November 18, 2005
Published online: July 28, 2006
Revised: October 12, 2005
Accepted: November 18, 2005
Published online: July 28, 2006
Abstract
Living donor liver transplantation (LDLT) is an alternative therapeutic option for patients with end-stage hepatitis C virus (HCV) cirrhosis because of the cadaveric organ shortage. HCV infection is now a leading indication for LDLT among adults worldwide, and there is a worse prognosis with HCV recurrence. The antivirus strategy after transplantation, however, is currently under debate. Recent updates on the clinical and therapeutic aspects of living donor liver transplantation for HCV are discussed in the present review.